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Abstract Many peripheral solid tumors such as sarcomas and carcinomas express tumor-
specific antigens that can serve as targets for immune effector T cells. Nevertheless, the
immune surveillance against clinically manifest carcinomas and sarcomas seems relatively
inefficient. Nave cytotoxic T cells are activated exclusively in secondary lymphoid or-
gans including the spleen and lymph nodes. Tumor antigen might be either cross-present-
ed to nave cytotoxic T cells by professional antigen-presenting cells (pAPC), or presented
directly by tumor cells that migrated to secondary lymphoid organs. Direct priming is
quite inefficient during early tumor development because metastasis to lymphoid organs is
usually limited to advanced stage diseases. Similarly, the process of cross-priming by
pAPC seems to depend on relatively large antigen amounts and on maturation stimuli for
dendritic cells, and both requirements may be limiting during initial tumorigenesis. There-
fore, the immunosurveillance of solid tumors may fail because they are ignored for too
long by the immune system. However, these situations may prove promising for the in-
duction of tumor-specific T cell immunity by vaccination, as the T cell repertoire against
these antigens has a nave phenotype and is not yet affected by tolerance mechanisms.
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Introduction
Cancer cells undergo series of genetic modifications during the oncogenic process, leading
to multiple cellular proteins (antigens) that are quantitatively or qualitatively different
from the parental cell. Different immune effectors are involved in the recognition of tumor
antigens, but there is considerable evidence for the central role of cytolytic CD8+ T lym-
phocytes (CTL) in mediating specific tumor immunity [1, 2]. During the past decades var-
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ious tumor antigens have been characterized [3, 4]. These antigens can be subdivided into
four major categories: (1) differentiation antigens, expressed in normal and neoplastic
cells of the same lineage; (2) overexpressed antigens with higher expression levels in tu-
mor tissues compared with normal tissues; (3) tumor-specific shared antigens, expressed
in different tumors but not in normal tissues, except for the group of cancer testis antigens
that is expressed in testis and placenta tissue; and (4) tumor-specific unique antigens, re-
sulting from mutations in a single tumor.
Despite the presentation of antigenic peptides by tumor cells on major histocompatibil-
ity complex (MHC) class I, CTL against most of these epitopes are not or not efficiently
activated. For differentiation antigens this may be explained by the thymic deletion of
high-avidity self-reactive CTL [5, 6]. However, also CTL responses to tumor-specific
antigens are often not induced, despite detectable antigen expression by the tumor cells.
Why anti-tumor cytotoxic T cells are not induced in this situation may depend on several
factors, including the localization of the tumor [7, 8], the activation status of professional
antigen-presenting cells (pAPC) [9, 10, 11], inhibitory molecules expressed by the tumor
[12] and others that will be discussed in this review.
The endogenous immune response to tumors
The idea that the immune system is involved in the control of tumors dates back to the
1950s when Burnet and Thomson [13] formulated the immune surveillance hypothesis.
They suggested that tumors continuously arise in the body, but that these tumors are rec-
ognized by a very efficient immune system that eliminates the tumor cells early before
they become clinically apparent. Clinically manifest tumors were seen as a rare event that
escaped efficient immunosurveillance. In the 70s nude mice became available that lack
thymic maturation of CTL. Surprisingly, these mice had a normal incidence of solid tu-
mors [14]. However, due to extrathymic T cell maturation, nude mice possess a small pop-
ulation of functional CTL. In parallel, patients receiving immunosuppressive drugs after
organ transplantation had a normal incidence of the most common solid tumors such as
breast, lung, or colon cancer [15, 16]. In contrast, the incidence of malignant lymphomas
is significantly higher in patients with congenital or acquired immunodeficiencies. In pa-
tients with primary congenital immunodeficiency the incidence of associated lymphopro-
liferative disorders (IALD) ranges from 0.7% for patients with X-linked agammaglobulin-
emia to 12–15% in patients with ataxia telangiectasia. In patients with post-transplant
lymphoproliferative disorders the incidence varies from 0.5% after bone marrow trans-
plantation to 10% after heart and lung transplantation. Although there are some differ-
ences between these IALD, they are often associated with Epstein-Barr virus infection
[17]. It is clear, therefore, that the immune system is involved in the control of lymphohe-
matopoietic and virus-induced tumors, but due to the normal incidence of spontaneous
solid tumors in nude mice and in immunocompromised patients, a central role of the im-
mune surveillance in the control of solid tumor development seemed questionable.
Experimental setups employed to analyze the effector mechanisms necessary for tumor
control often include the subcutaneous (s.c.) or intraperitoneal (i.p.) injection of carcinoma
or sarcoma cells in recipient mice depleted of or deficient in the effector mechanism of in-
terest. These experiments usually highlighted the importance of CD8+ T cells in a per-
forin-dependent control of various experimental tumor cell lines [18, 19]. Perforin is ex-
clusively expressed by natural killer (NK) cells and T cells, is essential for inducing tumor
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cell apoptosis in vitro, and perforin-deficient mice (pfp/–) show an increase in the growth
and metastasis of experimental tumors [18, 20]. In contrast, pfp–/– mice of up to
12 months of age are not abnormally prone to spontaneous malignancy. To accelerate tu-
mor development pfp–/– mice were crossed with p53-deficient mice, that have an in-
creased susceptibility to epithelial, lymphoid and connective tissue tumors. Lack of per-
forin expression in T and NK cells increased the incidence of disseminated lymphomas
but not of solid tumors [21]. These experiments illustrate that the control of tumor devel-
opment in experimental situations, especially after injection of single-cell suspensions
may be overestimated compared to its role in solid tumors that arise spontaneously after
clonal expansion of a transformed cell. In addition, even the effector mechanisms neces-
sary to control spontaneously arising tumors in the periphery may be different to the con-
trol of single cells experimentally injected i.p. or s.c. in salt solution.
More recent experiments analyzing the spontaneous tumor development in RAG-2–/–,
in STAT-1–/– and in RAG-2–/–STAT-1–/– mice renewed the interest in the immunosur-
veillance of solid tumors [22]. In contrast to nude mice that have some limited maturation
of functional T cells, RAG-2–/– mice are completely deficient in B and T cells; 50% of
RAG-2–/– mice developed benign adenomas and 50% adenocarcinomas of lung and intes-
tine at the age of 15–16 months. The incidence of malign disease was even more pro-
nounced with an incidence of 80% adenocarcinoma at the age of 12–18 months in RAG-
2–/–xSTAT-1–/– double-knockout mice that in addition lack IFN-g-meditated effector
mechanisms of innate immunity. Tumors derived from methylcholantrene-treated RAG-
2–/– mice were more immunogenic in transplantation experiments than tumors induced in
control mice, suggesting that the tumors that develop in the presence of a functional im-
mune system are under selective pressure to develop low immunogenic escape mutants, a
process that was termed “immunoediting”[23].
In contrast to the extensively studied role of CD8+ T cells in tumor control, the contri-
bution of other effector mechanisms of the acquired immune system is less well defined.
The importance of antibodies in the inhibition of solid tumors is not clearly understood
and remains controversial. Spontaneous anti-tumor antibodies are frequently detected in
the serum of cancer patients, and an increase in the titer seems to be associated with pro-
gression of the tumor [24, 25, 26, 27]. For p53-expressing tumors a correlation between
detectable anti-p53 antibodies and a poor prognosis has been documented [28]. Over the
last few years, the relative efficacy of anti-tumor monoclonal antibodies (mAb) for the
treatment of certain breast cancers or B cell lymphomas [29] renewed the interest of im-
munologists in anti-tumor humoral responses. Antibodies per se are not toxic for a virus-
infected cell or a tumor cell, but they act either by blocking vital signaling molecules on
the cell surface or by a secondary effector mechanism including antibody-dependent cellu-
lar cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [30]. Although
the relative importance of each effector mechanism in the protection against tumors re-
mains controversial and seems to depend on the experimental system analyzed, ADCC
might be the dominant effector mechanism in vivo. The relevance of CDC against tumors
in vivo remains to be shown, and is probably limited by the expression of complement
regulatory proteins on tumor cells. In mice, anti-melanoma antibodies inhibit tumor
growth in a Fcg receptor (FcgR)-dependent manner [31]. In addition, the importance of
the Fc-FcgR interaction for anti-tumor activity was shown for the clinically important an-
tibodies transtuzmab (Herceptin) and rituximab (Mabthera, Rituxan) as well as for intrace-
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rebral therapy with an anti-epidermal growth factor receptor antibody in a brain tumor
model [32].
The role of innate immune cells such as NK, natural killer T cells (NKT) and gdTCR+
T cells in immune surveillance remains limited to some experimental systems, although
these cells express perforin and many anti-tumor cytokines such as IFN-g and TNF-a [33,
34]. In contrast to abTCR+ T cells that are predominantly localized in secondary lym-
phoid organs, gdTCR+ T cells represent the majority of resident T cells in the skin and the
gut, termed intraepithelial lymphocytes. These cells may, therefore, represent a frontline
defense against tumors arising in the skin or the gut. Indeed, dTCR–/– mice are more sus-
ceptible to methylcholantrene-induced skin cancer and to tumor cell lines injected directly
intradermally [35]. Immune surveillance by intraepithelial lymphocytes was activated by
the murine NKG2d ligands Rae-1 and H60 [35, 36]. However, the tumor incidence was
lower than in bTCR–/– mice and tumors developed later, indicating that gdTCR play a role
in the local control of tumors, but there seems to be a predominant role of abTCR+ T cells
in tumor control. In addition, dTCR–/– have not been reported to be prone to increased risk
for spontaneous malignancy.
The activity of NK cells is balanced by opposing activating and inhibitory signals,
whereas the down-regulation of MHC class I molecules and the expression of NKG2d
have been identified favoring NK activation [37]. NK cells are responsible for tumor re-
jection and protection from metastasis in MHC class I-negative tumor models. Recent ex-
periments confirmed a role of the innate immune surveillance in the control of spontane-
ous B cell lymphomas, whereas the incidence of solid tumor was not reported to be in-
creased [38].
Although various effector mechanism of the immune system are involved in tumor im-
munosurveillance, most experimental data support the notion that eradication of solid tu-
mors rests predominantly on CD8+ T lymphocyte reactivity [1, 2, 23, 39]. It is therefore of
importance how other effector mechanisms of the immune system influence the resulting
CD8+ T cell response. An interesting possibility is that antibodies influence the induction
of cytotoxic T cells. Studies from the 70s showed that sera from rats with tumor regres-
sion blocked the cell-mediated destruction of sarcomas [40]. More recent experiments
documented an augmented rejection of tumor allografts by mice lacking B cells and an en-
hanced induction of an anti-tumor response in the absence of B cells [41]. It was speculat-
ed that APC, such as B cells, macrophages and dendritic cells (DC) compete for tumor an-
tigen, but an actual role of antibodies in this process could not be documented. In contrast,
antibodies have been shown to enhance cross-presentation of tumor antigens. Targeting
antigen to FcgR promoted cross-presentation and CTL induction by several orders of mag-
nitude in mouse bone marrow-derived DC [42] and recent in vitro experiments suggested
a role for anti-tumor antibodies in the induction of anti-tumor CTL. Coating of myeloma
cells with anti-syndecan antibodies increased cross-presentation and cross-priming of the
tumor antigens NY-ESO1 and MAGE3 [43]. In a mouse model, CD8+ T cell depletion
prevented treatment of established solid tumors with anti-tumor mAb, suggesting a role of
antibodies in the induction of CTL in vivo [44]. Similarly, NK cell activation has been
shown to influence CTL priming. MHC class Ilow tumor cells activate NK cells, which in
response prime DC to produce IL-12 and to induce anti-tumor CTL [45]. Taken together,
various effector mechanisms are involved in the control of solid tumors, and in many tu-
mor situations they may be non-redundant. In addition to their role in direct tumor control
in vivo, immunological effector mechanisms may also influence the resulting anti-tumor
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CTL response. However, the requirements for either enhancing or inhibiting tumor-specif-
ic CTL responses by antibodies or NK cells, and especially their relevance for the protec-
tion against tumors in vivo, remains to be analyzed in clearly defined model situations.
Induction of cytotoxic T cells
There is a critical threshold of T cell receptor (TCR) molecules to be engaged with pep-
tide-MHC molecules to trigger a detectable T cell response. In vitro experiments suggest-
ed that a small number of peptide-MHC complexes serially triggers up to approximately
200 TCR, leading to T cell activation [46]. The requisite number of occupied TCR can be
significantly decreased if costimulatory signals are provided. In situations where TCR
triggering becomes limiting, the provision of a costimulatory signal is crucial to reach the
threshold for activation and induction of a T cell response [47]. This leads to the concept
that a nave T cell requires two distinct signals for full activation [48, 49]: Signal one is
delivered by the interaction between TCR and antigenic peptides presented on MHC mo-
lecules. The second signal is provided by at least one of several antigen-nonspecific cos-
timulatory signals, including the interaction of CD28 on T cells with B7 family molecules
on pAPC. Additional second signals include members of the TNFR family (CD40-
CD40L, CD27-CD70, OX40-OX40L, 4–1BB-4–1BBL) [50, 51], as well as soluble mole-
cules such as IL-2, IL-12 and IL-18 and molecules involved in cell adhesion and T cell
stimulation such as LFA-1 and ICAM-1. Although all these costimulatory pathways stim-
ulate different intracellular signaling pathways and some of their roles may be non-redun-
dant, they all result in enhanced activation, proliferation, survival and effector function
[50, 51].
In vivo nave CTL have to interact and collaborate in organized lymphoid tissue with
APC to become activated [52, 53]. The term organized lymphoid tissue defines structures
such as follicles, marginal zone, germinal center, periarteriolar sheath and red pulp. These
anatomical structures determine the localization of antigen, cytokines, interleukins and by-
stander contacts via costimulatory molecules. Therefore, lymph nodes and the spleen pro-
vide the milieu necessary for lymphoid cell interactions and activation. Direct demonstra-
tion that secondary lymphoid organs play a pivotal role in adoptive immune responses de-
rived mainly from alymphoblastic aly/aly mice and from lymphotoxin-a-deficient (Lta–/–)
and lymphotoxin-b-receptor (LtbR–/–)-deficient mice [54, 55, 56]. The interpretation of
the immune responses in aly/aly, Lta–/– and LtbR–/– is complicated by the fact that, apart
from the lack of lymph nodes, these animals have other defects in the adaptive immune
system. Lta–/– or LtbR–/– mice have increased numbers of circulating T cells, and sponta-
neously develop massive infiltrates of activated lymphocytes in their peripheral tissues
[55, 56]. Therefore, the necessity of secondary lymphoid organs to induce an immune re-
sponse may be masked in these mice. Adoptive transfer experiments revealed that T cells
from aly/aly mice are functionally normal in a control C57BL/6 host [54, 57]. Aly/aly
mice generated detectable, but reduced, CTL responses after infection with vaccinia virus
and lymphocytic choriomeningitis virus (LCMV), and the elimination of these viruses was
either delayed or virtually impossible; irrespective of the dose or the route of infection,
aly/aly mice developed life-long LCMV persistence and splenectomized aly/aly mice did
not mount a CTL response at all after infection with LCMV [54]. More recently, it was
shown that splenectomized aly/aly mice did not mount a response to alloantigens after
heart transplantation [57]. In contrast to nave T cells that are activated by antigen within
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organized structures of secondary lymphoid organs, memory CTL activation and re-ex-
pansion seem to be independent of secondary lymphoid structures [58].
How long has antigen to be present in lymphoid organs for optimal expansion of cyto-
toxic T cells? Several groups have shown that a single brief encounter with antigen results
in at least eight to ten “programmed” cell divisions of the responding T cell [59]. The anti-
gen dose and persistence determines the peak size of the CD8+ T cell response by (1) re-
cruitment of antigen-specific precursors from the nave CD8+ T cell repertoire, and (2) in-
fluencing the total number of divisions. This peak expansion is followed by a contraction
of T cell numbers to a stable frequency of memory CTL. The contraction phase is initiated
by the absence of antigen, but also by the fact that effector CTL are prone to undergo cell
death due to the decreased expression of anti-apoptotic protein Bcl-2, c-IAP and tumor ne-
crosis factor receptor-associated factor 2 (TRAF-2), as well as due to direct induction of
apoptosis through FAS or TNFR signaling. In addition, cytokine starvation during the
peak of CTL expansion, especially of IL-2, may limit further expansion and contribute to
the contraction of the CD8+ T cell pool [60]. What happens if the antigen is not cleared
and persists at high levels? It is well documented that T cells do not react against antigens
that are continuously present in lymphoid organs. Antigen that is continuously present in
secondary lymphoid organs will activate nave T cells to proliferate and expand to a peak
similar to that of antigen only transiently present in lymphoid organs. However, despite
the persistence of the antigen, T cells do not continue to expand but, in contrast, undergo a
contraction phase, resulting in the deletion of all T cells specific for that antigen. The pro-
cess of activation followed by the physical deletion of T cells is termed exhaustion [61].
Some cytopathic persistent infections that are transmitted from mother to offspring, an
overwhelming infectious dose of a replicating virus or advanced stages of leukemia or
lymphoma will lead to this form of tolerance [62].
Therefore, the antigen amount, localization and persistence over time are crucial pa-
rameters for the induction of nave T cells (Fig. 1). The threshold for the activation of na-
ve T cells within lymphoid organs may be influenced by other effector mechanisms of the
immune system, as discussed above. For example, the expression of costimulatory mole-
cules on the APC (“cis”) or on other non-APC (“trans”) lowers the threshold of antigen
necessary for the induction of nave CTL [47]. The presentation of the peptide on the
MHC class I, together with costimulatory signals on the same cell, seems more efficient
than providing second signals in trans. However, we recently analyzed the contribution of
Fig. 1 Antigen dose over time in secondary lymphoid organs determines the resulting CTL response. The
horizontal dotted line determines the minimal amount of antigen necessary for the induction of a CTL re-
sponse, “threshold for CTL activation” (CTL cytolytic T lymphocyte)
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B7.1 expressed on a fibrosarcoma to the induction of nave T cells [7]. The same number
of B7.1-expressing or -non-expressing fibrosarcoma cells was necessary to induce an anti-
tumor CTL response when the tumor cells were injected directly into the spleen. In con-
trast, CTL priming in lymphatic organs was reduced by a factor of about 100 in CD28-de-
ficient mice, indicating that costimulatory molecules expressed in lymphatic organs may
lower the antigen-threshold necessary for CTL activation. The abundance of costimulatory
signals including B7.1, B7.2, CD40L, CD70, and soluble factors such as IL-2 are offered
most efficiently within the anatomic structure of secondary lymphoid organs in either a
bystander or a linked fashion. As outlined above, antibodies may crucially influence the
antigen distribution and, therefore, CTL priming (Fig. 1). Natural antibodies are an essen-
tial part of the first line of defense against pathogens and provide an important link to the
adaptive immune response. One important mechanism by which natural antibodies, but
probably also IgM and IgG antibodies of the adaptive immune response, enhance specific
CTL and antibody responses is the pooling of antigen to secondary lymphoid organs [63].
Within secondary lymphoid organs antibody-coated antigen may be more efficiently tar-
geted to and processed by FcgR-expressing DC [42, 64]. Furthermore, activation of the
complement cascade may enhance CD8+ T cell responses and lower the antigen amount
necessary for CTL activation [65].
Cross-priming versus direct priming
How then is the tumor-antigen transported, processed and presented to nave CTL in sec-
ondary lymphoid organs? There are two possibilities how peptides derived from tumor
antigens are presented on MHC class I molecules to nave CTL: (1) direct presentation on
tumor cells that migrated to secondary lymphoid organs, or (2) indirect, after uptake and
processing by pAPC, a process that is termed cross-presentation (Fig. 2). Cross-priming
describes the resulting CTL activation by cross-presented antigen. Similarly, cross-toler-
ance involves antigen processing and presentation via DC, but the specific T cells are not
induced but anergized [66, 67]. There is evidence that both pathways of antigen expres-
sion exist in vitro and in vivo. However, there is substantial controversy as to which of the
two pathways is of biological relevance [68, 69]. These differences can be partially at-
tributed to the experimental systems analyzed.
The first evidence for the concept of cross-priming was obtained in experiments by Be-
van [70], demonstrating that mice immunized with cells expressing foreign minor histo-
compatibility antigens mounted a self class I-restricted response, even if the cells lacked
the restricting class I molecule. Since then, various studies with H-Y and other minor his-
tocompatibility antigens have demonstrated a phenomenon that is compatible with cross-
priming or cross-presentation. However, it is interesting to note here that in these early
studies no cross-priming could be detected for tumor cells under similar experimental con-
ditions [70, 71]. This was explained by the rapid proliferation of tumor cells favoring one
dominant CTL subspecificity by direct induction.
Cross-priming assigns a central role to pAPC in the regulation of the immune response
by inducing nave T cells. Since the early experiments of Bevan, the understanding of the
molecular mechanisms allowing the access of exogenous proteins to the MHC class I
pathway of antigen presentation of pAPC has drastically increased (reviewed in [66]).
Proteins internalized through all pathways of endocytosis, including macropinocytosis, re-
Springer Semin Immun (2005) 27:19–35 25
ceptor-mediated endocytosis and phagocytosis, may be cross-presented. The process of
cross-presentation seems more efficient for apoptotic cells than for necrotic cells [72].
Two models explaining cross-presentation at a molecular level are consistent with the
present data. In the first model, the phagosome is self contained and associated with the
proteasome and the peptide-loading complex [73]. In the second model, external protein
have direct access to the endoplasmic reticulum [74].
Cross-presenting activity has been detected by macrophages, DC populations, B cells,
keratinocytes and L cells, but CD8+ DC are probably the important population cross-pre-
senting ovalbumin and herpes simplex virus epitopes [75]. Efficient cross-presentation re-
quires uptake of dead cells by immature DC, followed by the exposure to maturation stim-
uli. T cell division is induced by both immature and mature DC. However, full activation
of effector CTL requires proper activation (maturation) of DC [69]. Activation signals in-
clude innate-immunity triggers, such as ligands of Toll-like receptors, or adaptive immu-
nity triggers, such as CD40 ligand (CD40L), provided by activated CD4+ T cells [10, 67].
In addition, opsonized antigen by IgG molecules has not only been documented to facili-
tate antigen targeting to APC, but may also provide a ligand for DC activation [42, 76].
Usually, high antigen concentrations have been used to document cross-presentation in
vitro, but a recent report analyzing the efficiency of cross-presentation of vaccinia virus-
derived antigens by human DC revealed that this pathway may be very efficient and com-
parable to peptide pulsing with 10–100 nM [77]. Of course, one caveat in analyzing cross-
priming with potentially replicating agents, such as influenza or vaccinia virus, is the limi-
tation in the detection limit of replicating virus, so that infection of DC can never be ex-
cluded absolutely [72, 78, 79].
Fig. 2 Induction of an anti-tumor CTL response. Nave CD8+ T cells are induced in secondary lymphoid
organs either direct by tumor cells or indirect via antigen cross-presenting pAPC. Nave CD4+ T cells are
also induced in secondary lymphoid organs, but because most peripheral carcinomas and sarcomas are
MHC class II negative, only pAPC are able to activate CD4+ T cells. CD4+ T cell activation provides direct
help to CD8+ T cells and, in most tumor models, CTL responses are dependent on the activation of T helper
cells. In addition, CD4+ T cells provide signals to pAPC to induce their maturation (pAPC professional an-
tigen-presenting cell, DC dendritic cell)
26 Springer Semin Immun (2005) 27:19–35
In contrast to the usually well controllable situations in vitro, the detection of cross-
priming in vivo is more controversial and especially dependent on the readout system
used. Several methods were employed to analyze CTL activation in vivo as a consequence
of cross-presentation by APC: (1) CFSE dilution of TCR transgenic T cells, (2) lysis of
peptide-pulsed target cells after in vitro restimulation and expansion, (3) intracellular IFN-
g production after short in vitro restimulation with the respective peptide, (4) analysis of
specific CD8+ T cells by MHC class I tetramer staining, and (5) in vivo protection read-
outs. The adoptive transfer of CFSE-labeled T cells is definitely the most sensitive read-
out, leading to a precursor frequency of nave T cells of about 1:10–100. When compared
to the estimated physiological LCMV-GP33-specific precursor CTL frequency of 1 in
2105, this is 2,000–20,000 times higher [80]. In different tumor models expressing viral
antigens or ovalbumin as model tumor antigens, CFSE dilution as a consequence of anti-
gen cross-presentation by pAPC could be documented [81, 82]. These experiments re-
vealed that the process of cross-presentation in vivo is possible. However, due to the un-
physiological high precursor frequency in these TCR transgenic systems, they do not al-
low conclusions to be drawn regarding the physiological relevance in the induction of an
anti-tumor immune response in vivo. In non-transgenic systems, it was shown that minor
histocompatibility antigens, together with H-2b on cells, injected into F1 (bxd) mice prime
CTL that are H-2d restricted [70]. Other experimental systems using defined antigens con-
firmed that APC and CTL do necessarily have to express the same H-2 restriction for acti-
vation of CTL [72, 83]. However, it has to be emphasized that in these experimental sys-
tems the antigen-threshold for the induction of a CTL response is often changed (see
Fig. 1), e.g., the immunization with an allogenic cell induces T help that lowers the thresh-
old for (direct or indirect) CTL priming. Alternatively, the substitution with a H-2 non-
compatible bone marrow prevents the induction of CD4+ helper cells, reducing the thresh-
old for CTL priming. Since anti-tumor CTL responses are usually dependent on the induc-
tion of specific CD4+ helper cells and most tumor cells are MHC class II negative, it is
obvious that the resulting CTL response is dependent on pAPC, but these experiments nei-
ther prove nor exclude a physiological role of cross-presentation of tumor antigens in vivo
[7, 84]. Similarly, activation of NK cells by MHC non-matched tumor cells may provide
an environment ideal for CTL priming, i.e., lower the threshold of antigen necessary for
the detection of a CTL response. Therefore, only analysis of CTL responses to defined
peptides will allow conclusions to be drawn regarding cross-priming, whereas protection
experiments will not be conclusive. Because of these limitations, experiments in F1 mice
from syngeneic parents with different haplotypes may be most instructive since they allow
the analysis of direct and indirect CTL priming in the same experimental setting. Experi-
ments by Hang et al. [83] with a colon carcinoma cell line transfected with influenza nu-
cleoprotein (CT26-NP, H-2b) showed that these cells primed H-2d-NP336-restricted CTL
in F1 (bxd) mice. However, specific lysis of H-2d NP336-restricted CTL was very low
(10–20% at an E:T of 100:1) and a comparison with the efficiency of direct priming by
the tumor cells in lymphoid organs was not possible in this experimental system. The role
of cross-priming on the peptide level in vivo was assessed in a comparable experimental
situation using LCMV-GP and nucleoprotein (NP)-expressing splenocytes and tumor cells
(Table 1). (H-2bxH-2d) F1 mice were analyzed for the generation of H-2d- and H-2b-re-
stricted CTL after immunization with splenocytes from mice that express the LCMV-GP
under the H-2 Kb promoter and LCMV-GP or -NP-transfected MC57G (fibrosarcoma, H-
2b), D2 (fibrosarcoma, H-2d), EL4 (lymphoma, H-2b) and P815 (mastocytoma, H-2d) tu-
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mor cells [7, 8]. The resulting CTL response was, in all cases, limited to the haplotype of
the immunizing cells, indicating that the efficiency of cross-priming in vivo is low when
compared to direct CTL priming. Usually for these kinds of experiments tumor cells are
injected as single-cell suspensions i.p. or s.c., an immunization route that is different from
a physiologically growing peripheral tumor and which allows the migration of tumor cells
to local lymph nodes and to the spleen, and probably favors direct CTL induction [85]. In
summary, cross-priming has been very well documented and analyzed in vitro, and the
process of cross-priming can also be detected in vivo. However, due to experimental limi-
tations, the conditions when cross-priming is the predominant way, or when direct priming
is more efficient in the induction of an anti-tumor immune response, are difficult to assess.
In addition, the two processes may be even redundant for the priming of anti-tumor im-
mune responses [86].
Nevertheless, several points can be concluded from the current literature. First, direct
priming of tumor cells only occurs in secondary lymphoid organs and the direct injection
of antigen-expressing tumor cells into secondary lymphoid organs is about 100–1,000
times more efficient in the induction of a CTL response than s.c. injection [7, 85]. Second-
ly, DC activation is necessary for cross-priming. Maturation stimuli are very efficiently
provided by infectious agents, but may be limiting in a situation of a peripheral self or tu-
mor antigen [69]. Thirdly, relatively large amounts of antigen are necessary to induce
cross-priming. Activation of OT-I transgenic T cells is only observed in a transgenic
mouse expressing high antigen levels in the pancreatic islets, but not in a strain with low
ovalbumin expression [82]. In addition, cross-priming of p14 TCR transgenic T cells was
not detectable in a rat insulin promoter (RIP)-GP transgenic mouse model [87]. However,
when these mice were crossed to RIP-Tag2 transgenic mice that develop insulinomas, tu-
mor growth enhanced cross-presentation, leading to limited T cell activation [81]. This
again may be due to an increased amount of antigen present due to tumor growth and/or
Table 1 Analysis of cross-priming versus direct priming of LCMV-GP and –NP-expressing tumor
cells and splenocytes. Tumor cell lines were transfected with either LCMV-GP or LCMV-NP.
LCMV-GP-expressing transgenic C57BL/6 (H-2b, DEE) were bred with B10.D2 mice to obtain
DEEbd F1 and DEEdd offspring. H-2b-restricted CD8+ CTL responses were analyzed using peptide
gp33–41 or np 394–402 pulsed target cells; H-2d-restricted CTL responses were analyzed against
gp283–294 or np118–126 pulsed target cells after 5 days in vitro restimulation. H-2b restricted CD4+
T cell responses were analyzed by measuring antibody responses after immunization with DNP cou-
pled to the helper epitope gp60–80 (H-2b). Data are summarized from [7, 8]
Cells Dose Recipient mice CD8+ CD4+
H-2b H-2d H-2b
MC-GP (H-2b) 5106 i.p.. F1 (H-2bxH-2d) + – n.d.
MC-GP (H-2b) apoptotic 4107 i.p. H-2b – n.d. n.d.
MC-GP (H-2b)) 5106 i.p. H-2b + n.d. +
MC-GP (H-2b) anti-CD4 treatmenta 5106 i.p. H-2b – n.d. n.d.
EL-GP (H-2b) 5106 i.p. F1 (H-2bxH-2d) + – n.d.
D2-GP (H-2d) 5106 i.p. F1 (H-2bxH-2d) – + n.d.
P815-NP (H-2d) 5106 i.p. F1 (H-2bxH-2d) – + n.d.
DEE (H-2bb) 2106 i.v. F1 (H-2bxH-2d) + – n.d.
DEE (H-2bd) 2106 i.v. F1 (H-2bxH-2d) + + n.d.
DEE (H-2dd) 2106 i.v. F1 (H-2bxH-2d) – + +
DEE (H-2bb) anti-CD4 treatment 2106 i.v. H-2b – n.d. n.d.
a M. Matter, unpublished data
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due to APC maturation in the proinflammatory environment associated with the tumor. In
line with a relatively high antigen expression necessary for cross-priming of nave CTL,
Spiotto et al. [88] described that solid tumors expressing a model tumor antigen at lower
levels grew, whereas the same solid tumors expressing the antigen in a tamoxifen-regulat-
ed Cre-loxP system to higher levels were rejected due to cross-priming. Cross-priming
does not only depend on a high synthesis rate of the protein, but also on its stability. This
may be the reason why cross-priming is less efficiently reached with peptides derived
from signal sequences, which are usually rapidly degraded after synthesis [89].
Immunological ignorance
The question then remains as to what happens if the antigen amount in secondary lym-
phoid organs, over a sufficient period of time, is not sufficient to activate nave CTL, but
the antigen is expressed exclusively on cells outside secondary lymphoid organs. The
analysis of this question precludes a strict control of the localization of the antigen-ex-
pressing cells. This is difficult to obtain with transplantation experiments, for example us-
ing minor histocompatibility differences, since passenger leukocytes expressing the mAg
may migrate through lymphatic vessels and reach the draining lymph node. However, the
availability of transgenic mice expressing a model antigen under a tissue selective promot-
er allowed the analysis of immune responses to peripheral self antigens. RIP-GP transgen-
ic mice express the LCMV-GP under the RIP [87]. These RIP-GP mice did not sponta-
neously develop diabetes. However, LCMV-GP-specific CTL in RIP-GP mice could be
activated by immunization with DC expressing LCMV-GP or after infection with replicat-
ing LCMV. Interestingly, infection of the same mice with a recombinant vaccinia virus
expressing the GP of LCMV resulted in CTL priming, but failed to induce diabetes. These
experiments showed that induction of a CTL response alone is not sufficient to cause im-
munopathological autoimmune disease, but that there is an important quantitative require-
ment of effector CTL generated, i.e., LCMV infection induces about 100–1,000 times
more effector T cells than recombinant vaccinia virus. These experiments illustrate that T
cells specific for LCMV-GP are present, but because the antigen is expressed strictly out-
side secondary lymphoid organs and the antigen does not reach local lymph nodes in suf-
ficient quantity over a sufficient period, no specific CTL are induced, and the peripheral
antigen is ignored by the immune system [61]. Immunological ignorance therefore de-
scribes a situation in which reactive CD8+ T cells in an individual have not encountered
the target antigen and have a nave phenotype.
Similarly, transgenic mice were produced expressing membrane-bound OVA under the
RIP. When RIP-OVA mice were crossed to OT-1 mice, which produce OVA-specific
CD8+ T cells, double-transgenic mice showed deletion of OT-1 cells, probably due to thy-
mic expression of OVA. However, adoptively transferred OT-1 cells into RIP-OVA mice
expressed activation molecules at the cell surface and entered cell cycle in draining, but
not in non-draining lymph nodes due to cross-presentation [90]. In later experiments the
same group analyzed RIP-OVA mice with high and with low antigen expression in the
pancreatic islets, and showed that the level of antigen expressed in peripheral tissues must
be relatively high to be cross-presented by pAPC [82]. In this model, cross-presentation
induced an initial activation followed by a deletion of the specific CTL. Below this anti-
gen level, peripheral antigens were ignored by nave OT-1 cells.
Springer Semin Immun (2005) 27:19–35 29
Therefore, immunological ignorance of antigens expressed in peripheral tissues is de-
pendent on several factors (Fig. 1 and Table 2): Firstly, the antigen is exclusively ex-
pressed on cells that do not or not efficiently migrate to secondary lymphoid organs. This
is probably true for most self and tumor antigens; secondly, cross-presentation of these pe-
ripheral antigens is not sufficient for CTL activation due to the level of antigen expression
or inadequate maturation of DC, as discussed above.
Ignorance of peripheral antigens must be separated from peripheral tolerance. The term
tolerance usually describes situations where CTL have encountered antigen, but they are
not properly activated or they are actively suppressed by regulatory mechanisms. Suppres-
sion of self-reactive T cells might be important for maintaining immunological unrespon-
siveness to self constituents (i.e., self tolerance) and preventing autoimmune disease. Re-
cent studies have demonstrated that CD25+CD4+ regulatory T cells control not only auto-
immune reactions but also other immune responses, including tumor immunity (reviewed
in [91]).
Ignorance of solid tumors
Tumor antigens are in many respects quite similar to self antigens, and comparable rules
may apply for the induction of an autoimmune or anti-tumor CTL response. Tumors de-
velop without the apparent induction of a CTL response and the tumor-specific CTL have
a nave phenotype. CD8+ T cells remain in a nave phenotype if they have not been acti-
vated by tumor cells reaching local lymph nodes or by pAPC cross-presenting tumor anti-
gens. Since peripheral tumors may originate from one malignant cell outside secondary
lymphoid organs and metastasis to local lymph nodes occurs at relatively advanced stages
of the disease, no or only few tumor cells may reach lymphoid organs early to induce tu-
mor-specific CTL. In addition, tumor cells reaching secondary lymphoid organs have sev-
eral strategies to avoid efficient CTL induction, including the development of antigen- or
MHC class I-loss variants [92]. We recently reported that B16 melanoma cells injected di-
rectly into lymphoid organs avoid contact with nave CTL by encapsulation [7]. Similarly,
the requirements to reach the antigen load necessary for cross-priming may not be reached
easily in spontaneous tumor development. The initially small tumors do not provide the
antigen amount crucial for reaching cross-presentation by pAPC. This may be due to the
limited number of tumor cells, but also due to relatively low expression levels of some tu-
mor antigens. It has to be kept in mind that tumor experiments in mice are often done with
tumor cell lines overexpressing antigens under the control of very strong viral promoters,
Table 2 Mechanisms limiting antigen-presentation on MHC class I in lymph nodes
Direct – Late and inefficient migration of tumor cells to lymph nodes
– MHC-class I down-regulation
– Low tumor antigen expression
– Expression of inhibitory molecules
– Lack of costimulation
– Walling off
Indirect – Inefficient cross–presentation of antigen on MHC class I
– Low level of tumor antigen expression
– Inefficient maturation of dendritic cells
– Limited number of apoptotic tumor cells to release antigen
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and the transfected tumor cells are selected for maximal antigen expression. This selection
of tumor cells expressing high antigen levels is necessary to reliably analyze immune re-
sponses. However, there are only few situations with spontaneous tumors in which the tu-
mor antigens are expressed under such strong promoters. Examples are fusion proteins,
where some tumor antigens are expressed under very strong promoters such as BCR-ABL
[93] or virus-induced tumors where the viral antigen is at the same time a tumor-associat-
ed antigen [17]. However, the situation for most solid tumors may be quite different since
most tumor antigens are only expressed at low to moderate levels. In addition, tumors re-
semble normal healthy tissue in many ways, and often cause little or no DC activation [69,
81]. Therefore, both the direct and indirect induction of nave CTL by tumors is inefficient
in vivo, especially during early tumor development, and peripheral tumors are ignored by
CD8+ T cells. In more advanced stages of disease, a sufficient number of tumor cells may
reach lymphoid organs, and/or, for some tumors, the antigen amount may reach the level
necessary for cross-priming, leading to activation of nave CTL. In these advanced stage
diseases the induced CTL response contrasts a very large tumor burden and is, therefore,
often not sufficient to eradicate all tumor cells before escape variants occur [23, 92].
In situations where solid tumors are ignored by nave CTL, vaccination protocols may
be most efficient because no tolerance mechanism prevents the induction of the specific
CD8+ T cells. We recently showed, for a growing fibrosarcoma expressing the LCMV-GP
as model tumor antigen, that detectable CTL responses are relatively easily induced by
vaccination. In contrast, rejection of growing tumors is demanding and requires several
booster immunizations [8, 94]. Detailed analysis of the CTL frequencies induced by vari-
ous vaccination protocols with LCMV-gp33-expressing DC revealed that repetitive immu-
nizations during the initial 8–10 days were necessary to reach a high frequency of effector
cells, probably due to efficient recruitment of nave CTL. After the initial expansion, fur-
ther booster immunizations did not augment the frequency of effector cells, but were nec-
essary to keep the cells activated with lytic function. In this experimental system even the
repetitive injection of the tumor cells as single-cell suspensions led to the rejection of es-
tablished tumors, indicating that ignorance is broken if antigen-expressing cells reach
lymphoid organs [95, 96].
Conclusion
Nave tumor-specific CTL are induced in secondary lymphoid organs, including lymph
nodes and the spleen. Solid tumors develop outside organized lymphoid structures and
during early oncogenesis they often do not efficiently induce a CTL response. Nave CTL
are only activated if the tumor antigen is presented in secondary lymphoid organs over a
sufficiently long period of time. Tumor antigen might be either cross-presented to nave
CTL by pAPC or directly by tumor cells that migrated (metastasized) to secondary lym-
phoid organs. Both processes are quite inefficient during early tumor development. Metas-
tasis is, for most tumors, associated with advanced disease, and does not occur during ear-
ly tumor development. The process of cross-presentation in vivo seems to depend on large
antigen amounts and on the proper activation (maturation) of DC. Tumors usually start
from a single malignant cell and therefore only offer limited inflammatory stimuli for DC
maturation and a limited amount of antigen to be cross-presented during early stages of
the disease. As a consequence, peripheral tumors may grow because they are ignored by
the immune system for too long. In more advanced tumor stages, migrating tumor cells in-
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duce an immune response in local lymph nodes or, in some situations, tumor antigen lev-
els might be sufficient to cross-prime nave CTL. The induced CTL response often con-
trasts a large tumor burden and is not sufficient to eliminate the tumor completely, but
will select for less immunogenic escape mutants. Ignorance to tumors and to self antigens
can be broken simply by providing syngeneic antigen-expressing cells to lymphoid or-
gans. Due to the low tumor burden, the nave phenotype of tumor-specific CTL and the
absence of tolerance mechanisms, vaccination protocols against tumors might be very ef-
ficient in a situation of peripheral ignorance of solid tumors.
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